Skip to main content
Premium Trial:

Request an Annual Quote

Maxygen Gains $3.4M from DOD for Protein Reshuffling Technology

NEW YORK (GenomeWeb News) – Maxygen has received a $3.4 million grant from the US Department of Defense to develop its genetic reshuffling technology through a collaboration with the DNA-based vaccine services provider Aldevron, the company said today.
The firm’s ParallelaVax system is used for rapid, high-throughput screening of vaccine candidates in animals.
Maxygen’s technology allows genes for selected proteins to be reshuffled and screened, resulting in a protein with a desired profile. The Redwood City, Calif.-based company said that so far its program has developed an HIV-1 envelope protein and multiple variants with increased activity relative to specific HIV strains.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.